Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.
(2015) In Dementia and Geriatric Cognitive Disorders 40(5-6). p.297-310- Abstract
- Background/Aims: Factors including rate of disease progression, different aspects of cholinesterase inhibitor (ChEI) treatment, and use of community-based services might affect the longitudinal outcome of Alzheimer’s disease (AD). Whether these factors alter life expectancy in AD is unclear. We therefore examined the association between long-term ChEI therapy and survival.
Methods: The present study included 1,021 patients with a clinical diagnosis of AD and a Mini-Mental State Examination score of 10–26 at baseline from a 3-year, prospective, multicenter study of ChEI therapy in clinical practice. The relationship of potential predictors with mortality was analyzed using Cox regression models.
Results: After up to 16... (More) - Background/Aims: Factors including rate of disease progression, different aspects of cholinesterase inhibitor (ChEI) treatment, and use of community-based services might affect the longitudinal outcome of Alzheimer’s disease (AD). Whether these factors alter life expectancy in AD is unclear. We therefore examined the association between long-term ChEI therapy and survival.
Methods: The present study included 1,021 patients with a clinical diagnosis of AD and a Mini-Mental State Examination score of 10–26 at baseline from a 3-year, prospective, multicenter study of ChEI therapy in clinical practice. The relationship of potential predictors with mortality was analyzed using Cox regression models.
Results: After up to 16 years of follow-up, 841 (82%) of the participants had died. In the Alzheimer’s Disease Assessment Scale-cognitive subscale, a mean decline of >= 4 points/year or >= 2 points/year on the Physical Self-Maintenance Scale was a risk factor for an earlier death. In the multivariate models, longer survival was associated with higher ChEI dose and longer duration of treatment. Users of community-based services at baseline exhibited a 1 year shorter mean life expectancy than nonusers.
Conclusion: A longer survival time can be anticipated for AD patients with slower deterioration, who receive and tolerate higher ChEI doses and a longer duration of treatment. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8043307
- author
- Wattmo, Carina LU ; Londos, Elisabet LU and Minthon, Lennart LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cognition, Activities of daily living, Home help services, Adult day care, Mortality, Statistical models
- in
- Dementia and Geriatric Cognitive Disorders
- volume
- 40
- issue
- 5-6
- pages
- 297 - 310
- publisher
- Karger
- external identifiers
-
- pmid:26335053
- wos:000363429400006
- scopus:84941249271
- pmid:26335053
- ISSN
- 1420-8008
- DOI
- 10.1159/000437050
- language
- English
- LU publication?
- yes
- id
- 6ad7dc27-f5e2-4f1b-a5f8-aaaaafdfcdca (old id 8043307)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26335053?dopt=Abstract
- date added to LUP
- 2016-04-01 10:31:34
- date last changed
- 2022-05-17 23:46:22
@article{6ad7dc27-f5e2-4f1b-a5f8-aaaaafdfcdca,
abstract = {{Background/Aims: Factors including rate of disease progression, different aspects of cholinesterase inhibitor (ChEI) treatment, and use of community-based services might affect the longitudinal outcome of Alzheimer’s disease (AD). Whether these factors alter life expectancy in AD is unclear. We therefore examined the association between long-term ChEI therapy and survival.<br/><br>
Methods: The present study included 1,021 patients with a clinical diagnosis of AD and a Mini-Mental State Examination score of 10–26 at baseline from a 3-year, prospective, multicenter study of ChEI therapy in clinical practice. The relationship of potential predictors with mortality was analyzed using Cox regression models.<br/><br>
Results: After up to 16 years of follow-up, 841 (82%) of the participants had died. In the Alzheimer’s Disease Assessment Scale-cognitive subscale, a mean decline of >= 4 points/year or >= 2 points/year on the Physical Self-Maintenance Scale was a risk factor for an earlier death. In the multivariate models, longer survival was associated with higher ChEI dose and longer duration of treatment. Users of community-based services at baseline exhibited a 1 year shorter mean life expectancy than nonusers.<br/><br>
Conclusion: A longer survival time can be anticipated for AD patients with slower deterioration, who receive and tolerate higher ChEI doses and a longer duration of treatment.}},
author = {{Wattmo, Carina and Londos, Elisabet and Minthon, Lennart}},
issn = {{1420-8008}},
keywords = {{Cognition; Activities of daily living; Home help services; Adult day care; Mortality; Statistical models}},
language = {{eng}},
number = {{5-6}},
pages = {{297--310}},
publisher = {{Karger}},
series = {{Dementia and Geriatric Cognitive Disorders}},
title = {{Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.}},
url = {{https://lup.lub.lu.se/search/files/1917722/8862746.pdf}},
doi = {{10.1159/000437050}},
volume = {{40}},
year = {{2015}},
}